HEALTH ALERT! If you have any of the following, please call our office before coming in for your appointment: Fever AND cough; Fever OR cough and recent travel (domestic or international to any destination); Recent international travel to areas impacted by the Coronavirus (2019-nCoV) within the last 14 days; OR close contact with someone who has traveled outside the US or been exposed to the Coronavirus. Read more

Treatments & Services

Available Trials



Breast

  • USOR 20258: PH2 GDC-9545 ER+/HER2- MBC

    A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared with Physician's Choice of Endocrine Monotherapy in Patients With Previously Treated Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (WO42312)

    Available at Arlington Heights, Niles

  • USOR 19054: STAR Ph3 Tuca/Placebo + T-DM1 HER2+

    A Randomized, Double-Blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable, Locally-Advanced, or Metastatic HER2+ Breast Cancer. (HER2CLIMB-02)(SGNTUC-016)

    Available at Arlington Heights, Niles


Cholangiocarcinoma


Colorectal


Endometrial

  • USOR 19221: PH3 Plac Carbo Pacil Dura +/- Olap DUO -E

    A Randomized, Multicentre, Double-Blind, Placebo-Controlled, Phase III Study of First-Line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer. (DUO-E) (D9311C00001)(GOG-3041)(ENGOT-EN10)

    Available at Arlington Heights, Niles


Gynecological/Ovarian

  • USOR 20225 STAR Ph2 Ak104 Cervical Cancer

    A Phase 2, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects with Recurrent or Metastatic Cervical Cancer (AK104-201-AU) (Akesobio Australia)

    Available at Arlington Heights

  • USOR 19200: PH3 Mirve Sora Fallopian

    MIRASOL: A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression. (IMGN853-0416)

    Available at Arlington Heights, Niles


Hematology

  • USOR 18130: Ph3 Itacitinib GVHD (GRAVITAS309)

    INCB 39110-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

    Available at Niles

  • USOR 08160: PNH Registry

    PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)

    Available at Niles, Arlington Heights


Leukemia


Lung - Non-Small Cell Lung

  • USOR 20331 STAR Ph2 VS-6766 FAK inhib KRAS-MT NSCLC

    NOW OPEN: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and in Combination with Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (VS-6766-202) (Verastem)

    Available at Niles

  • USOR 20269 STAR PH3 MRTX849 Doce NSCLC

    New: A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-012) (Mirati Therapeutics)

    Available at Arlington Heights, Niles

  • USOR 20270 Ph2 MRTX849 Pembro NSCLC KRAS

    NEW: A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation. (849-007) (Mirati Therapeutics)

    Available at Arlington Heights, Niles

  • USOR 20381:  MYLUNG Study Part 2

    NEW Observational Research Trial to Improve Testing and Treatment Protocols for NSCLC: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium)

    Available at Arlington Heights, Niles

  • USOR 20137: PH3 Atez Tira Dura Sg 3 NSCLC

    A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable, Stage III, Non-Small Cell Lung Cancer, Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03) (GO41854)

    Available at Arlington Heights, Niles

  • USOR 19018: Ph 3 Sit + Nivo vs. Docetaxel NSCLC

    516-005: A Randomized, Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

    Available at Arlington Heights, Niles

  • USOR 19192: Ph3 Tira atezo NSCLC

    A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-Tigit Antibody, In Combination with Atezolizumab, Compared with Placebo In Combination With Atezolizumab, In Patients With Previously Untreated, Locally Advanced, Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer. (GO41717)

    Available at Arlington Heights, Niles

  • USOR 19044: Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)

    D9103C00001: A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Unresected Stage I/II, Lymph-Node Negative, Non-Small Cell Lung Cancer. (PACIFIC-4/RTOG-3515)

    Available at Niles


Lymphoma

  • USOR 20343 Ph3 LOXO-305 vs Inv Choice IdeIR or BR

    Now Open: A Phase 3, Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

    Available at Arlington Heights, Niles

  • USOR 19062:  Ph 1b/3 Taze w/ R2 R/R Fol Lymph

    A Phase 1B/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma (EZH-302)

    Available at Arlington Heights, Niles

  • USOR 20219: PH2 Brentux + CHP in Tx Naive PTCL

    A Dual-Cohort, Open-Label, Phase 2, Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects with Peripheral T-Cell Lymphoma (PTCL) with Less Than 10% CD30 Expression. (SGN35-032)

    Available at Niles

  • USOR 20144: PH3 Bren Vedo Lena Ritux r/r BC Lymph

    A Randomized, Double-Blind, Placebo-Controlled, Active-Comparator, Multi-Center, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.(SGN35-031)

    Available at Arlington Heights, Niles

  • USOR 16065: TGR-1202 +/- Ublituximab in NHL

    A Phase 2b, Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma. (UTX-TGR-205)

    Available at Niles, Arlington Heights

  • USOR 11282: STAR BV in pts w/1L cHL or PTCL

    A Phase 2, Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients with Significant Comorbidities Ineligible for Standard Chemotherapy.(SGN35-015)

    Available at Niles


Multiple Myeloma

  • USOR 19247: PH3 Dara/Len vs Len NDMM

    A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

    Available at Arlington Heights, Niles


Myelomas

  • USOR 18230: Ph3 R/R MM (DREAMM 7)

    DREAMM 7: A Multicenter, Open- Label, Randomized, Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma (207503.)

    Available at Arlington Heights, Niles


Pancreas


PNH

  • USOR 08160: PNH Registry

    PNH Registry: Primary Objective of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry will Collect Data to Evaluate Safety Data Specific to the Use of Solaris and to Characterize the Progression of PNH as well as Clinical Outcomes, Mortality and Morbidity in Solaris and Non-Solaris Treated Patients. Secondary Objective is Raising PNH Awareness in the Medical Community and Patient/Potential Patient Population. (M07-001)

    Available at Niles, Arlington Heights


Prostate


Solid Tumor

  • USOR 19151: STAR Ph1/2 MRTX849 Solids KRAS G12C

    A Phase 1/2, Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Sold Tumors with KRAS G12C Mutation (849-001)

    Available at Niles

  • USOR 19079: STAR Ph2 Pemigatinib Solids FGFR

    A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)(INCB54828-207)

    Available at Arlington Heights


STAR: Selected Trials Available for Accelerated Four Week Rollout